Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (MUT) braf kinase: evidence of activity in melanoma brain metastases (METS)

G. V. Long, R. F. Kefford, P. J. A. Carr, M. P. Brown, M. Curtis, B. Ma, P. Lebowitz, K. B. Kim, R. Kurzrock, G. Falchook

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)12-12
Number of pages1
JournalAnnals of Oncology
Publication statusPublished - Oct 2010
Externally publishedYes
Event35th European-Society-for-Medical-Oncology (ESMO) Congress - Milan, Italy
Duration: 8 Oct 201012 Oct 2010

Cite this